Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster

Ayumi President Kiyonori Karasawa Back in FY2018, Ayumi Pharmaceutical was hit by an unexpected supply hitch due to spiking demand for its Enbrel (etanercept) biosimilar, which was then Japan’s only follow-on for the major rheumatoid arthritis (RA) drug. With manufacturing...read more